|
RBMS2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.71699999995667E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.3110999992102E-08 |
| Normal-vs-Stage2 |
2.085200E-01 |
| Normal-vs-Stage3 |
2.008700E-04 |
| Normal-vs-Stage4 |
6.963500E-04 |
| Stage1-vs-Stage2 |
2.299900E-02 |
| Stage1-vs-Stage3 |
2.951600E-01 |
| Stage1-vs-Stage4 |
4.685400E-01 |
| Stage2-vs-Stage3 |
1.431160E-01 |
| Stage2-vs-Stage4 |
1.476380E-01 |
| Stage3-vs-Stage4 |
8.617800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.66800000034328E-07 |
| Normal-vs-AfricanAmerican |
1.963690E-03 |
| Normal-vs-Asian |
2.93040000043376E-07 |
| Caucasian-vs-AfricanAmerican |
4.721400E-01 |
| Caucasian-vs-Asian |
1.392420E-02 |
| AfricanAmerican-vs-Asian |
3.462600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.91519999995327E-06 |
| Normal-vs-Female |
8.04459999947937E-07 |
| Male-vs-Female |
5.255800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
7.64050001045291E-09 |
| Normal-vs-Age(41-60Yrs) |
1.751999999966E-06 |
| Normal-vs-Age(61-80Yrs) |
4.856100E-02 |
| Normal-vs-Age(81-100Yrs) |
6.912000E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.378010E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.800700E-04 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.760500E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.165600E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.870990E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.192600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.560200E-01 |
| Classical-VS-Follicular |
1.12840004007353E-09 |
| Classical-VS-Other |
5.229400E-01 |
| Classical-VS-Normal |
1.71110015045883E-10 |
| Tall-VS-Follicular |
3.341100E-03 |
| Tall-VS-Other |
7.795600E-01 |
| Tall-VS-Normal |
3.574000E-04 |
| Follicular-VS-Other |
1.791230E-01 |
| Follicular-VS-Normal |
9.772200E-01 |
| Other-VS-Normal |
5.662400E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
7.623600E-04 |
| Normal-vs-N1 |
4.1857000000034E-05 |
| N0-vs-N1 |
8.937900E-02 |
|
|
